- Home
- SNTI vs GALT Comparison
SNTI vs GALT Comparison
Compare SNTI & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- GALT
- Stock Information
- Founded
- SNTI 2016
- GALT 2000
- Country
- SNTI United States
- GALT United States
- Employees
- SNTI N/A
- GALT N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- GALT Health Care
- Exchange
- SNTI Nasdaq
- GALT Nasdaq
- Market Cap
- SNTI 85.3M
- GALT 83.5M
- IPO Year
- SNTI N/A
- GALT N/A
- Fundamental
- Price
- SNTI $3.56
- GALT $1.30
- Analyst Decision
- SNTI Strong Buy
- GALT Hold
- Analyst Count
- SNTI 1
- GALT 1
- Target Price
- SNTI $12.00
- GALT N/A
- AVG Volume (30 Days)
- SNTI 25.9K
- GALT 158.8K
- Earning Date
- SNTI 05-06-2025
- GALT 05-15-2025
- Dividend Yield
- SNTI N/A
- GALT N/A
- EPS Growth
- SNTI N/A
- GALT N/A
- EPS
- SNTI N/A
- GALT N/A
- Revenue
- SNTI N/A
- GALT N/A
- Revenue This Year
- SNTI N/A
- GALT N/A
- Revenue Next Year
- SNTI N/A
- GALT N/A
- P/E Ratio
- SNTI N/A
- GALT N/A
- Revenue Growth
- SNTI N/A
- GALT N/A
- 52 Week Low
- SNTI $1.52
- GALT $0.73
- 52 Week High
- SNTI $16.94
- GALT $3.17
- Technical
- Relative Strength Index (RSI)
- SNTI 58.08
- GALT 48.22
- Support Level
- SNTI $3.04
- GALT $1.22
- Resistance Level
- SNTI $3.25
- GALT $1.37
- Average True Range (ATR)
- SNTI 0.23
- GALT 0.08
- MACD
- SNTI 0.04
- GALT 0.00
- Stochastic Oscillator
- SNTI 89.83
- GALT 56.25
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.